Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Fineline Cube Apr 27, 2026
Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Fineline Cube Apr 27, 2026
Company Drug

CDC Provisionally Recommends Pfizer’s Abrysvo for Maternal Immunization Against RSV

Fineline Cube Sep 25, 2023

The US Centers for Disease Control and Prevention (CDC) has issued a provisional recommendation for...

Company Drug

Boehringer Ingelheim and Eli Lilly’s Jardiance Wins FDA Approval for CKD Prevention

Fineline Cube Sep 25, 2023

Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have received regulatory approval from the US...

Company Drug

MSD’s Keytruda Meets Endpoints in Urothelial Carcinoma Trial but Misses in NSCLC Study

Fineline Cube Sep 25, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading global pharmaceutical company, last week released...

Company Drug

Betta Pharmaceuticals’ CFT8919 Accepted for Review by China’s NMPA for EGFR L858R Solid Tumors

Fineline Cube Sep 25, 2023

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a China-based pharmaceutical company, has announced that the National...

Company

Simcere Pharmaceutical Reports 25.2% Revenue Growth in 2023 Interim Financials

Fineline Cube Sep 25, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has released its interim financial report for 2023, revealing...

Company

3D Medicines’ H1 2023 Report Highlights 70.3% YOY Growth in Envafolimab Sales

Fineline Cube Sep 25, 2023

China-based oncology specialist 3D Medicines (HKG: 1244) has released its financial report for the first...

Company Medical Device

Acotec Scientific Holdings Receives Japanese Marketing Approval for Peripheral Support Catheter Vericor

Fineline Cube Sep 25, 2023

Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it...

Company Deals

Chime Biologics Partners with Panolos Bioscience to Speed Up Multi-Specific Protein Development

Fineline Cube Sep 25, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics Ltd has announced a strategic cooperation...

Company Deals

Hangzhou Qihan Biotechnology Secures Over $13.8 Million in Pre-Series B Financing

Fineline Cube Sep 25, 2023

Hangzhou Qihan Biotechnology Co., Ltd, a leading xenotransplantation specialist based in China, has reportedly raised...

Company Drug

CNIPA Upholds Alynlam Pharmaceutical’s PCSK9 siRNA Patent Against Junshi Biosciences Challenge

Fineline Cube Sep 25, 2023

The China National Intellectual Property Administration (CNIPA) has rejected a challenge filed by Junshi Biosciences...

Company Deals

Everest Medicines Partners with Kezar Life Sciences to Commercialize Zetomipzomib in Asia

Fineline Cube Sep 25, 2023

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a strategic collaboration and license...

Company Deals

I-Mab Regains Global Rights to CD47 Antibody Lemzoparlimab Following AbbVie Deal Termination

Fineline Cube Sep 25, 2023

China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has received a notice from US-based AbbVie Global Enterprises...

Company Drug

Sanofi’s Dupixent Secures NMPA Approval for Pruritigo Nodosa Treatment in China

Fineline Cube Sep 22, 2023

France-based pharmaceutical company Sanofi (NASDAQ: SNY) has announced that it has received another indication approval...

Company Legal / IP Policy / Regulatory

EU Chamber of Commerce in China Releases Position Paper, Addresses Pharma and Healthcare

Fineline Cube Sep 22, 2023

The EU Chamber of Commerce in China has released its bi-annual “European Business in China...

Company Legal / IP

Eli Lilly Sues US Sellers of Counterfeit Mounjaro Products

Fineline Cube Sep 22, 2023

Pharmaceutical giant Eli Lilly (NYSE: LLY) has filed a lawsuit in the United States against...

Company Deals

Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals for $462 Million

Fineline Cube Sep 22, 2023

Healthcare fund Gurnet Point Capital (GPC) and Novo Holdings, the controlling shareholder of Novo Nordisk...

Company

MicroPort Scientific Reports 19% Revenue Growth in H1 2023, Driven by Diverse Interventions

Fineline Cube Sep 22, 2023

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its financial report for...

Company R&D

Amgen Launches Global Collaboration Network to Advance Oncology Research

Fineline Cube Sep 22, 2023

Amgen (NASDAQ: AMGN) has announced the launch of a new collaboration network that connects its...

Company Deals

Roche’s Genentech Partners with Orionis Biosciences for Molecular Glue Therapies

Fineline Cube Sep 22, 2023

Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has announced a partnership with...

Company Drug

Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Solid Tumor Trial

Fineline Cube Sep 22, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that it...

Posts pagination

1 … 459 460 461 … 657

Recent updates

  • Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
  • Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease
  • Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback
  • China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio
  • Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Company

Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease

Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.